NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,828.93 +317.24 (+1.92%) CRUDE OIL
83.45 +0.09 (+0.11%) GOLD FUTURES
2,336.40 -5.70 (-0.24%) DOW
38,503.69 +263.71 (+0.69%) Bitcoin GBP
53,251.14 -674.46 (-1.25%)
Novozymes A/S (NVZMF)
| Previous close | 52.51 |
| Open | 52.51 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 52.51 - 52.51 |
| 52-week range | 38.85 - 62.80 |
| Volume | |
| Avg. volume | 2,487 |
| Market cap | 25.539B |
| Beta (5Y monthly) | 0.48 |
| PE ratio (TTM) | 33.88 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 0.89 (1.69%) |
| Ex-dividend date | 01 May 2024 |
| 1y target est | N/A |
- Globe Newswire
Resolutions from the Extraordinary Shareholders’ Meeting 2024
Company Announcement no. 10 March 4, 2024Today an extraordinary shareholders’ meeting was conducted. The following resolutions were made: Adoption of Novonesis A/S as secondary name and amendment of the Articles of Association in accordance herewithElection of Jesper Brandgaard as Vice Chair of the Board of DirectorsElection of Lise Kaae, Kevin Lane and Kim Stratton as members of the Board of Directors Following the extraordinary shareholders’ meeting, the Board of Directors consists of the foll
- GlobeNewswire
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed
Settlement of the combination of Novozymes and Chr. Hansen Holding successfully completed February 2, 2024Company announcement No. 07 On January 29, 2024, following the satisfaction of all conditions precedent, the combination of Novozymes A/S ("Novozymes") and Chr. Hansen Holding A/S ("Chr. Hansen") by way of a statutory merger of the two companies (the "Combination") was successfully completed. Reference is made to Novozymes' company announcement no. 2 of January 29, 2024. As previously announ
- GlobeNewswire
Legacy Novozymes delivers solid last full-year results
Legacy Novozymes is delivering solid growth and earnings in a year characterized by changing market demands, with 6% organic sales growth in Q4 and 5% organic sales growth in 2023. This marks the last financial reporting from legacy Novozymes, and the new company, Novonesis, is already a reality. COPENHAGEN, Denmark – February 1, 2024. In the 2023 financial year, legacy Novozymes delivers 5% organic sales growth – 6% organic sales growth in the fourth quarter alone – an EBIT-margin before specia
